Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V7CF
|
|||
| Former ID |
DAP000168
|
|||
| Drug Name |
Indinavir
|
|||
| Synonyms |
Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1] | |
| Therapeutic Class |
Anti-HIV Agents
|
|||
| Company |
Merck & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C36H47N5O4
|
|||
| Canonical SMILES |
CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
|
|||
| InChI |
1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
|
|||
| InChIKey |
CBVCZFGXHXORBI-PXQQMZJSSA-N
|
|||
| CAS Number |
CAS 150378-17-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9263, 583813, 601472, 822078, 824057, 830610, 832455, 832456, 832457, 834483, 7846196, 7888933, 7979603, 8030462, 8187130, 10317595, 10317604, 10317607, 14765204, 14862973, 17422095, 26697187, 29211926, 46391630, 46392153, 46392154, 46392339, 46393133, 46393134, 46393135, 46393136, 46393839, 46393841, 46393842, 46393914, 46506442, 50064484, 92717923, 93166536, 93167159, 103179607, 104322011, 104829412, 124892212, 126628679, 127336447, 127336448, 127336449, 127336450, 127602164
|
|||
| ChEBI ID |
CHEBI:44032
|
|||
| ADReCS Drug ID | BADD_D01150 ; BADD_D01151 | |||
| SuperDrug ATC ID |
J05AE02
|
|||
| SuperDrug CAS ID |
cas=150378179
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Approved antiretroviral drugs. Antiretroviral Drugs. Company report of AVERT. 2009. | |||
| REF 2 | Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.